Tyra Biosciences’ Dabogratinib: FGFR3 Selectivity as a Platform for Two Blockbuster Indications

Core Thesis

Tyra Biosciences’ pipeline is built around dabogratinib, a FGFR3-selective inhibitor that addresses two large, under-served indications—intermediate-risk non-muscle invasive bladder cancer (NMIBC) and achondroplasia (ACH). The key structural advantage over peers is selective FGFR3 inhibition, which avoids FGFR1/2-mediated toxicities (e.g., hypophosphatemia) and enables higher, more effective dosing. The investment case hinges on two upcoming catalysts (mid-2026 NMIBC interim data, 6-month ACH height velocity readout) that could validate the platform and de-risk Phase 3 starts. The market currently undervalues both the oral convenience advantage in NMIBC and the potential for FGFR3 selectivity to unlock broader skeletal benefits in ACH beyond height.

The NMIBC Opportunity: Oral Convenience vs. Catheter Burden

Dabogratinib targets a ~70% complete response (CR) rate in intermediate-risk NMIBC via an oral regimen. Management considers this threshold—not higher efficacy—the key benchmark for Phase 3 success, because balancing tolerability and durability matters more in a low-progression-risk population. Current standard of care requires repeated catheter-based intravesical administrations, creating significant patient burden and low adoption in community settings where most patients are treated. A well-tolerated oral drug with comparable efficacy would shift the treatment paradigm.

Investment implication: If dabogratinib achieves CR rates of ~70% with durable responses, it could capture a meaningful share of the ~600,000 prevalent NMIBC patients in the US alone. The oral route eliminates the procedural burden entirely, potentially accelerating adoption even without superiority over intravesical therapy. Positive mid-2026 data would represent a major de-risking event that justifies significant upside.

Achondroplasia: FGFR3 Selectivity Enables Greater Dose Escalation and Broader Outcomes

Dabogratinib’s FGFR3 selectivity allows dose escalation that pan-FGFR inhibitors cannot achieve. BBIO’s infigratinib is limited by off-target FGFR1/2 toxicities (hypophosphatemia), capping its effective dose and targeting depth. By avoiding this class effect, Tyra can push dabogratinib to higher doses, potentially yielding ~1cm+ incremental height gain beyond current standards. Management also targets broader skeletal outcomes—bone proportionality, mobility, spinal stenosis reduction—which regulators may accept as endpoints beyond annualized height velocity (AHV).

Investment implication: If 6-month AHV data confirms meaningful height velocity improvement without safety signal, dabogratinib could surpass infigratinib’s efficacy profile. The differentiated ability to pursue skeletal function endpoints may create commercial differentiation and a broader label. Failure to demonstrate superiority would cede the ACH market to BBIO and severely limit Tyra’s total addressable market.

SNAP Platform as a Sustainable Competitive Moat

Eight years of investment in structural biology capabilities have yielded proprietary datasets enabling rapid co-crystal generation and precise drug design. This platform is not limited to FGFR3; Tyra has additional programs (TYRA-430, TYRA-200) targeting FGFR4/3 and FGFR1/2/3 respectively, with high unmet need. Management views the SNAP platform as highly translatable across targets, giving Tyra a structural advantage in drug design vs. peers.

Investment implication: A successful dabogratinib program validates the platform, not just the molecule. Positive clinical data would strengthen confidence in Tyra’s broader pipeline and ability to target additional FGFR-driven indications with the same approach. The platform is an option on future value creation, but only if dabogratinib succeeds in NMIBC or ACH.

Key Risks

Valuation and Trade Implication

Tyra is a binary catalyst-driven opportunity over the next 12–18 months. The stock price today reflects minimal probability of success in both NMIBC and ACH. Positive mid-2026 data in either indication would unlock blockbuster potential and justify significant upside. Failure would likely result in severe devaluation. The primary near-term re-rating event is the NMIBC interim data, which is more binary and higher-conviction than the ACH data given the clearer ~70% CR benchmark. We view the risk/reward as asymmetric to the upside if NMIBC data meets or exceeds the target.

Appendix: Dabogratinib vs. Infigratinib in Achondroplasia